# Semaglutide Treatment On Coronary Progression

> **NCT03985384** · PHASE4 · COMPLETED · sponsor: **Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center** · enrollment: 140 (actual)

## Conditions studied

- Type 2 Diabetes
- Coronary Artery Disease

## Interventions

- **DRUG:** Semaglutide 2 MG/1.5 ML Subcutaneous Solution
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03985384
- **Lead sponsor:** Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-04-30
- **Primary completion:** 2022-12-27
- **Final completion:** 2022-12-27
- **Target enrollment:** 140 (ACTUAL)
- **Last updated:** 2023-10-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03985384

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03985384, "Semaglutide Treatment On Coronary Progression". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03985384. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*